Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Hadzijusufovic Emir,

Beiträge für wissenschaftliche Veranstaltungen

Vortrag

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2018): Direct Effects of Ponatinib on Vascular Endothelial Cells: a Potential Explanation for Development of Vascular Adverse Events in CML Patients. Frontiers in CardioVascular Biology 2018; APR 20-22, 2018; Vienna, Austria. 2018.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2017): Effects of histamine receptor blockers on growth and IgE-dependent histamine release of canine neoplastic mast cells. 64-64.-Veterinary Cancer Society Congress; OCT 26-28, 2017; Portland, United States (USA).

Hadzijusufovic, E (2017): In vitro Models for Canine Mast Cell Research. -Comparative Oncology Mast Cell Meeti; MAR 24-25, 2017; Vienna, Austria.

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2017): Effects of Ponatinib on Vascular Endothelial Cells as Possible Explanation for Drug-Related Adverse Events Seen in Patients with CML. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; OCT 12-15, 2017; Estoril, Portugal. 2017.

Blatt, K; Cerny-Reiterer, S; Schwaab, J; Sotlar, K; Eisenwort, G; Stefanzl, G; Hoermann, G; Mayerhofer, M; Schneeweiss, M; Knapp, S; Rülicke, T; Hadzijusufovic, E; Bauer, K; Smiljkovic, D; Willmann, M [and 3 others] (2016): Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastozytosis. 50-50.-Jahrestagung der DGHO, OeGHO, SGMO und SGH; OCT 15, 2016; Leipzig, GERMANY.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor 1 antagonists on growth and survival of canine neoplastic mast cells. 8329-8329.-LBG Meeting for Health Sciences.; NOV 28-29, 2016; Vienna, AUSTRIA.

Hadzijusufovic, E; Kirchmair, R; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Valent, P (2016): Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego, CA, United States (USA), DEC 03-06, 2016. Blood (128), 22

Keller, A; Peter, B; Zuber, J; Berger, D; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2016): Targeting BRD4 as a potential therapeutic approach in JAK2 V617F+ myeloproliferative neoplasms. 8341-8341.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Valent, P; Willmann, M; Bauer, K; Blatt, K; Sotlar, K; Schwaab, J; Hoermann, G; Hadzijusufovic, E; Reiter, A; Horny, H; Rülicke, T (2016): Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis. 170-170.-17th Annual Congress of EUSAAT; AUG 24-27, 2016; Linz, AUSTRIA.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann; M (2015): The Ki-1 antigen (CD30) is a novel target for brentuximab vedotin in neoplastic canine mast cells. -ESVONC Annual Congress; MAY 28-30, 2015 ; Krakow, POLAND.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B [and 6 others] (2015): An update of functional data regarding the pro-atherogenic and anti-angiogenic effects of nilotinib in patients with Ph+ CML. Frühjahrstagung der ÖGHO und der AHOP - Oral presentation and Young Investigator Meeting Award, Salzburg, AUSTRIA, Austria, APR 23-25, 2015. memo - Magazine of European Medical Oncology (8), S 1 3-3.

Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Hoermann, G; Mayerhofer, M; Boudot, C; Gouilleux, F; Müllauer, L; Moriggl, R; Valent, P (2015): Activated STAT5 as novel stem cell target in JAK2 V617F positive myeloproliferative neoplasms (MPN). 20th Congress of the European Hematology Association, Vienna, AUSTRIA, Austria, JUN 11-14, 2015. Haematologica / The Hematology Journal (100), s1 521-521.

Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): The KI-1 Antigen (CD30) Is A Novel Marker And Potential Therapeutic Target In Advanced Systemic Mastocytosis. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 514-514.

Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Stefanzl, G; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): Evaluation of the Ki-1 antigen (CD30) as a novel marker and target in advanced mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 219-220.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Sadovnik, I; Hoermann, G; Jilma, B; Sperr, WR [and 6 others] (2014): Pro-Atherogenic And Anti-Angiogenic Effects Of Nilotinib On Endothelial Cells: A Potential Mechanism To Explain Vasculopathies In Cml Patients Treated With Nilotinib. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 510-510.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph+ CML. -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; OCT 10-14, 2014; Hamburg, GERMANY.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Nilotinib may exert Pro-Atherogenic and Anti-Angiogenic Effects on Endothelial Cells: A Potential Explanation for Vasculopathy in CML. 2nd Vascular Biology Meeting at the Medical University of Vienna.; JAN 24, 2014; Vienna, AUSTRIA. 2014.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U [and 5 others] (2014): Nilotinib induces Pro-Atherogenic and Anti-Angiogenic Effects on Human Vascular Endothelial Cells: A Potential Explanation for Drug-induced Vasculopathies in CML Patients. Frühjahrstagung der ÖGHO und der AHOP, Innsbruck, AUSTRIA, Austria, APR 10-12, 2014. Magazine of European Medical Oncology (7), S1 3-3.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hormann, G; Jilma, B; Sperr, WR [and 6 others] (2014): Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph plus CML. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 300-300.

Keller, A; Willmann, M; Valent, P; Hadzijusufovic, E (2014): Evaluation of the JAK2-STAT5 pathway as a therapeutic target in canine mastocytomas. -ECVIM-CA congress; SEP 4-6, 2014; Mainz, GERMANY.

Wedeh, G; Cerny-Reiterer, S; Hadzijusufovic, E; Eisenwort, G; Herrmann, H; Blatt, K; Muellauer, L; Schwaab, J; Bradner, JE; Sperr, WR; Reiter, A; Horny, HP; Willmann, M; Zuber, J; Arock, M; Valent, P (2014): Bromodomain- containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 198-199.

Wedeh, G; Cerny-Reiterer, S; Hadzijusufovic, E; Herrmann, H; Blatt, K; Eisenwort, G; Hoermann, G; Sperr, WR; Muellauer, L; Vakoc, CR; Bradner, JE; Horny, H; Zuber, J; Arock, M; Valent, P (2014): The Epigenetic Reader Brd4 Serves As A Novel Marker And Target In Aggressive Systemic Mastocytosis And Mast Cell Leukemia. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 514-515.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Wojta, J; Wolf, D [and 3 others] (2013): Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects on Vascular Endothelial Cells: A Potential Explanation for Drug-Induced Vasculopathy in CML. -55th Annual ASH Meeting; DEC 7-10, 2013; New Orleans, USA.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Wojta, J; Wolf, D [and 3 others] (2013): Evaluation of potential mechanisms underlying nilotinib-induced vasculopathy in CML: evidence that nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on endothelial cells. -15th ESH - iCMLf International Conference on CML - Biology and Therapy; SEP 26-29, 2013; Estoril, PORTUGAL.

Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Sadovnik, I; Pecnard, E; Gouilleux, F; Valent, P (2013): Expression of phosphorylated STAT5 in the putative stem cell population of JAK2 V617F transformed myeloproliferative neoplasms. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, Austria, OKT 18-22, 2013. Onkologie (36), S7 288-288.

Hadzijusufovic, E; Schur, F; Cerny-Reiterer, S; Pecnard, E; Gouilleux, F; Valent, P (2013): Expression of activated STAT5 in neoplastic stem cells in JAK2 V617F-transformed myeloproliferative neoplasms. -Second ESH-EHA Scientific Workshop on Leukemic and Cancer Stem Cells: Malignant Stem Cells and their Microenvironment; APR 25-27, 2013; Mandelieu, FRANCE.

Hadzijusufovic, E; Schur, F; Cerny-Reiterer, S; Pecnard, E; Gouilleux, F; Valent, P (2013): Expression of activated STAT5 in neoplastic stem cells in JAK2 V617F-transformed myeloproliferative neoplasms. Second ESH-EHA Scientific Workshop on Leukemic and Cancer Stem Cells: Malignant Stem Cells and their Microenvironment; APR 25-27, 2013; Mandelieu, FRANCE. 2013.

Peter, B; Winter, G; Blatt, K; Rix, U; Benett, KL; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, SH; Roesel, J; Manley, P; Superti-Furga, G; Valent, P (2013): Evaluation of the effects of the PKC412-metabolites CGP52421 and CGP62221 on proliferation and viability of neoplastic mast cells and IgE dependent secretion of histamine. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, Austria, OCT 18-19, 2013. Onkologie (36) 214-215.

Ghanim, V; Herrmann, H; Hadzijusufovic, E; Peter, B; Blatt, K; Schuch, K; Cerny-Reiterer, S; Mirkina, I; Heller, G; Zochbauer-Muller, S; Karlic, H; Pickl, WF; Valent, P (2011): 5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 1478-1478.

Hadzijusufovic, E; Hörmann, G; Peter, B; Herrmann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Mayerhofer, M; Valent, P (2011): Establishment of Novel Mast Cell Lines. -Annual Meeting of European Competence Network on Mastocytosis; NOV 18-19, 2011; Istanbul, TURKEY.

Blatt, K; Herrmann, H; Mirkina, I; Hadzijusufovic, E; Peter, B; Marth, K; Valenta, R; Valent, P (2010): The dual PI3 kinase/mTOR inhibitor NVP-BEZ235 acts as a suppressor of growth and function of human mast cells and basophils. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Germany, OKT 1-5, 2010. Onkologie (33), Suppl. 6 221-221.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT are Associated with Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Mast Cells. 89-89.-6th PhD Symposium, Medical University Vienna; JUN 16-17, 2010; Vienna, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): NI-1: A Novel Canine Mast Cell Line with a Unique kit Mutation and Resistance against Masatinib. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like-kinase-1 (Plk-1) as a novel molecular target in neoplastic mast cells in advanced systemic mastocytosis. -ÖGHO Frühjahrstagung; APR 8-10, 2010; Bregenz, AUSTRIA.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase 1 (Plk-1) as a novel drug target in canine and human neoplastic mast cells. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase-1 (Plk-1) is expressed in neoplastic mast cells and is a potential new target in advanced systemic mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Germany, OKT 1-5, 2010. Onkologie (33), Suppl. 6 206-206.

Hadzijusufovic, E; Peter, B; Willmann, M; Valent, P (2009): Effects of Histamine Recepter Antagonists on Growth and Survival of Neoplastic Mast Cells. -Annual Meeting of European Competence Network on Mastocytosis; NOV 13-14, 2009; Gdansk, POLAND.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The pan Bcl-2 inhibitor Obatoclax induces apoptosis and growth arrest in neoplastic mast cells in systemic mastocytosis. -7th Congress of the European Competence Network on Mastocytosis (ECNM); NOV 12-13, 2009; Gdansk, POLAND.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic Obatoclax induces Apoptosis and Growth Inhibition in Human and Canine Neoplastic Mast Cells. 233-233.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identifi cation of heat shock protein (Hsp32) as a novel therapeutic target in neoplastic mast cells. ESVONC autumn meeting, Budapest, Hungary, Hungary, 13–15 September, 2007. Vet Comp Oncol (6), 1 84-85.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Konto, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. 28-29.-4th PhD Symposium, Medical University of Vienna; MAY 28-29, 2008; Vienna, AUSTRIA.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R;Gruze, A; Kneidinger, M;Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein (Hsp32) as a Novel Therapeutic Target in Neoplastic Mast Cells. 194--17th ECVIM-CA Congress; Sep 13-15, 2007; Budapest, HUNGARY.

Poster

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2018): Ponatinib effects on endothelial cells as possible cause of vascular side effects in patients with CML. EMBO Workshop: Cellular signalling and cancer therapy; SEP 14-18, 2018; Cavtat, Croatia. 2018.

Hadzijusufovic, E; Hoermann, G; Herndlhofer, S; Sperr, WR; Jilma, B; Schernthaner, GH; Valent, P (2017): Age-related somatic mutations and the ESC-SCORE predict the occurrence of vascular adverse events in CML patients treated with nilotinib. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; OCT 12-15, 2017; Estoril, Portugal. 2017.

Hadzijusufovic E; Hoermann G; Herndlhofer S; Sperr WR; Jilma B; Schernthaner GH; Valent P (2017): Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients During Nilotinib Therapy. 59th Annual ASH Meeting, Atlanta, GA, United States (USA), DEZ 9-12, 2017. Blood (130), S1 1619-1619.

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2017): Effects of ponatinib on endothelial cells may explain the occurrence of vascular adverse events in ponatinib-treated patients with CML. Frühjahrstagung der ÖGHO und der AHOP, Bregenz, Austria, APR 6-8, 2017. memo - Magazine of European Medical Oncology (10) 23-23.

Schneeweiss, M; Peter, B; Bibi, S; Blatt, K; Jawhar, M; Berger, D; Stefanzl, G; Herndlhofer, S; Sperr, WR; Hadzijusufovic, E; Gleixner, KV; Reiter, A; Arock, M; Valent, P (2017): The Novel Switch Control Inhibitor Dcc-2618 Counteracts Growth and Survival Of Various Neoplastic Cells, Including Mast Cells, Eosinophils, and Monocytes, In Patients With Systemic Mastocytosis. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 276-277. Open Access Logo

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Hoermann, G; Reifinger, M; Pirker, A; Valent, P; Willmann M (2016): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor Antagonists on Canine Neoplastic Mast Cells. 205-205.-ESVCP - ESVONC Congress; OCT 20-22, 2016; Nantes, FRANCE.

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2016): Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib. 58th Annual ASH Meeting, San Diego, CA, USA, United States (USA), DEC 3-6, 2016. Blood (128), 22 1883-1883.

Hadzijusufovic, E; Kirchmair, R; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Valent, P (2016): Delineation of effects of ponatinib on vascular endothelial cells: a potential basis and explanation for the occurrence of vascular adverse events in CML patients treated with ponatinib. LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA. 2016.

Keller, A; Peter, B; Zuber, J; Berger, D; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2016): Targeting of BRD4 as a novel therapeutic concept in JAK2 v617F+MPN. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, Denmark, JUN 09-12, 2016. Haematologica (101), S1 89-89.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M (2015): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -Frühjahrstagung der OeGHO & AHOP; APR 23-25, 2015; Salzburg, AUSTRIA.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M. (2015): Interleukin-4 modulates expression of CD30 in neoplastic canine mast cells. -Veterinary Cancer Society; OCT 15-17, 2015; Vienna, VA, USA.

Keller, A; Peter, B; Zuber, J; Staber, PB; Bettelheim, P; Valent, P; Hadzijusufovic, E (2015): Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+MPN Cells. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL, DEC 05-08, 2015. Blood (126), 23

Keller, A; Peter, B; Zuber, J; Valent, P; Hadzijusufovic, E (2015): Evaluation of BRD4 as potential target in JAK2 V617F+MPN cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Basel, Schweiz, Switzerland, OCT 09-13, 2015. Oncol Res Treat (38), S5 226-227.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Further evaluation of pro-atherogenic and anti-angiogenic effects of nilotinib in mice and in patients with Ph-chromosome+ CML. -56th Annual ASH Meeting; DEC 6-9, 2014; San Francisco, USA.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Ghanim, V; Sadovnik, I; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Jilma, B; Schernthaner, GH [and 7 others] (2014): Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib: A Potential Explanation for Atherosclerosis in CML. -LBG Meeting for Health Sciences; DEZ 9-10, 2014; Vienna, AUSTRIA.

Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Grebien, F; Eisenwort, G; Schgoer, W; Kaun, C; Herndlhofer, S; Theurl, M; Cerny-Reiterer, S; Hoermann, G; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B [and 6 others] (2014): Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome plus CML. 56th Annual ASH Meeting, San Francisco, USA, United States (USA), DEC 6-9, 2014. Blood (124), 21 1800.

Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): Effects of the multikinase inhibitor R763/AS703569 on growth and survival of neoplastic mast cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 285-285.

Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): The Multikinase Inhibitor R763/AS703569 Blocks Stat5 Activity And Induces Apoptosis In Neoplastic Human Mast Cells. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 126-126.

Hadzijusufovic, E; Keller, A; Schur, F; Cerny-Reiterer, S; Sadovnik, I; Pecnard, E; Gouilleux, F; Moriggl, R; Valent, P (2013): Expression of activated STAT5 in the putative stem cell fraction of JAK2 V617F-transformed myeloproliferative neoplasms. -1st LBG Health Sciences Meeting; DEC 2, 2013; Vienna, AUSTRIA.

Oida, K; Hadzijusufovic, E; Panakova, L; Roth-Walter, F; Singer, J; Fazekas, J; Willmann, M; Szalai, K; Tanaka, A; Matsuda, H; Jensen-Jarolim, E (2013): House dust mite allergens induce IgE-independent activation of canine mast cells NI-1. World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Milan, ITALY, Italy, JUN 22-26, 2013. Allergy (68) 669-669.

Peter, B; Winter, G; Blatt, K; Rix, U; Benett, K; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, S; Roesel, J; Manley, P; Superti-Furga, G; Valent, P (2013): Evaluation Of Growth-Inhibitory And Histamine Release-Targeting Effects Of Pkc412 And Its Metabolites On Neoplastic Mast Cells By Chemical Proteomics Profiling And Target Validation. 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013. Haematologica (98), S1 407-407.

Gleixner, KV; Blatt, K; Peter, B; Hadzijusufovic, E; Valent, P (2011): Ponatinib Exerts Growth-Inhibitory Effects on Neoplstic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 1492-1492.

Hadzijusufovic, E; Herndlhofer, S; Aichberger, KJ; Ghanim, V; Suppan, V; Cerny-Reiterer, S; Sperr, WR; Valent, P (2011): Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML. 53rd ASH Annual Meeting and Exposition, San Diego, USA, United States (USA), DEC 10-13, 2011. Blood (118), 21 632-632.

Hadzijusufovic, E; Mirkina, I; Krepler, C; Mikula, M; Strommer, S; Wacheck, V; Stella, A; Höller, C; Pehamberger, H; Valent, P (2011): Melanoma-Initiating Cells Reside Within the EPOR+ and EPOR- Subfraction of Patient-Derived Clonal Tumor Cells. -Second Workshop Leukemic and Cancer Stem Cells; APR 29 - MAY 1, 2011; Mandelieu, FRANCE.

Peter, B; Blatt, K; Stefanzl, G; Hadzijusufovic, E; Dutreix, C; Gross, SH; Roesel, JL; Valent, P (2011): The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States (USA), DEC 10-13, 2011. Blood (118), 21 616-617.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 15th Congress of the European Hematology Association, Barcelona, SPAIN, Spain, JUN 10-14, 2010. Haematologica (95), S2 357-357.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): KIT Mutations Predict Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Human and Canine Mast Cells. 17-17.-Frühjahrstagung der ÖGHO und der AHOP; APR 8-10, 2010; Bregenz, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 357-357.-15th Congress of the European Hematology Association; JUN 10-14, 2010; Barcelona, SPAIN.

Peter, B; Gleixner, K; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, W; Pickl, W; Valent, P (2010): Identification Of Polo-Like Kinase-1 (Plk-1) As A Novel Drug Target In Neoplastic Mast Cells In Systemic Mastocytosis. 15th Annual Meeting of the European-Hematology-Association, Barcelona, SPAIN, Spain, JUN 10-13, 2010. Haematol-Hematol J (95), Suppl. 2 0446.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like kinase-1 (Plk-1) as a novel drug target in neoplastic mast cells in systemic mastocytosis. 357-357.-15th Congress of the European Haematology Association; JUN 10-13, 2010; Barcelona, SPAIN.

Peter, B; Herrmann, H; Gleixner, KV; Hadzijusufovic, E; Laffer, S; Schuch, K; Pickl, W; Sarno, SM; Willmann, M; Valent, P (2010): The Aurora Kinase Inhibitor R763/AS703569 Exerts Major Growth Inhibitory and Apoptosis Inducing Effects on Neoplastic Mast Cells. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 04-07, 2010. Blood (116), 21 1620-1620.

Hadzijusufovic, E; Gleixner, KV; Peter, B; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The H1 Receptor Antagonists Terfendine and Loratadine inhibit Growth and induce Apoptosis in Neoplastic Mast Cells. Annual Meeting of the Austrian Society of Haematology and Oncology, Salzburg, AUSTRIA, Austria, APR 16-18, 2009. memo - Magazine of European Medical Oncology (2), S 2 6-6.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Gleixner, KV; Gruze, A; Kneidinger, M; Thaiwong, T; Pickl, WF; Yuzbasiyan-Gurkan, V; Willmann, M; Valent, P (2009): Antiproliferative Effects of Four Tyrosine Kinase Inhibitors on Neoplastic Feline Mast Cells Exhibiting a kit Exon-8 ITD Mutation. 267-267.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Peter, B; Aichberger, K; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The Bh3 Mimetic Gx015-070 (Obatoclax) Induces Apoptosis And Growth Inhibition In Neoplastic Mast Cells. 14th Annual Meeting of the European-Hematology-Association, Berlin, GERMANY, Germany, JUN 04-07, 2009. Haematol-Hematol J (94), Suppl. 2 305.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic GX015-070 (Obatoclax) induces Apoptosis and Growth Inhibition in Neoplastic Mast Cells. -14th Congress of the European Hematology Association; JUN 4-7, 2010; Berlin, GERMANY.

Peter, B; Hadzijusufovic, E; Schuch, K; Blatt, K; Gleixner, KV; Pickl, WF; Willmann, M; Valent, P (2009): Evaluation of antineoplastic effects of INNO-406 on human and canine neoplastic mast cells. -Frühjahrstagung der ÖGHO und der AHOP; APR 12-14, 2009; Salzburg, AUSTRIA.

Hadzijusufovic, E; Gleixner, KV; Gruze, A; Kneidinger, M; Baumgartner, C; Pickl, WF; Willmann, M; Valent, P (2008): The H1-Receptor Antagonists Loratadine and Terfenadine inhibit Proliferation and Survival of Neoplastic Mast Cells. 53-53.-ESVONC and VCS First Joint Meeting; FEB 28 - MAR 1, 2008; Copenhagen, DENMARK.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent (2008): Identification of the Tyrosine Kinase Receptor Kit as a Molecular Target in Neoplastic Ferline Mast Cells. 98-98.-28th Annual VCS Conference; OCT 18-21, 2008; Seattle, USA.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Evaluation of growth-inhibitory effects of kit tyrosine kinase inhibitors on feline neoplastic mast cells. 215-215.-18th ECVIM-CA Congress; SEP 4-6, 2008; Ghent, BELGIUM.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Antiproliferative Effects of KIT Tyrosine Kinase Inhibitors in Feline Neoplastic Mast Cells. Frühjahrstagung 2008 der Österreichischen Gesellschaft für Hämatologie und Onkologie und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich (AHOP), Innsbruck, Austria, Austria, APR 10-12, 2008. Magazine of European Medical Oncology (1), Suppl. 1 10-10.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. ÖGHO und AHOP Frühjahrstagung, Vienna, AUSTRIA, Austria, Apr 12-14, 2007 . Wiener medizinische Wochenschrift / Supplement (157), 121 16.

Hadzijusufovic, EH; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samoorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Hiroshi, M; Willman, M; Valent, P (2007): Identification of heme oxygenase-1 (HO-1=Hsp32) as a novel therapeutic target in canine mastocytoma cells. 12th Congress of the European Hematology Association, Vienna, Austria, Austria, June 7 – 10, 2007 . Haematol-Hematol J (92) 489-490.

Poster mit Vortrag

Hadzijusufovic, E; Kirchmair, R; Krall, N; Huber, K; Theurl, M; Gamperl, S; Lener, D; Gutmann, C; Stanzl, U; Kirsch, A; Frank, S; Superti-Furga, G; Valent, P (2017): Effects of Ponatinib on Vascular Endothelial Cells As Possible Explanation for Drug-Related Adverse Events Seen in Patients with CML. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; OCT 12-15, 2017; Estoril, Portugal. 2017.

© Veterinärmedizinische Universität Wien Hilfe und Downloads